Novel medications, including GLP-1 receptor agonists (GLP-1 RA), are becoming a cornerstone of obesity management of metabolic disease given demonstrated improvements in glycemia, adiposity, and cardiovascular outcomes (5). This evidence concerns the gene GLP1R and Obesity.